Page last updated: 2024-10-24

candesartan cilexetil and Albuminuria

candesartan cilexetil has been researched along with Albuminuria in 15 studies

candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects

Albuminuria: The presence of albumin in the urine, an indicator of KIDNEY DISEASES.

Research Excerpts

ExcerptRelevanceReference
"CHILI T2D was a non-interventional, open-label, non-controlled, multicentre study in clinical practice that evaluated 4110 patients with type 2 diabetes, uncontrolled hypertension and microalbuminuria who were being prescribed a fixed-dose combination of candesartan cilexetil 16 mg/HCTZ 12."9.14Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study. ( Bramlage, P; Ketelhut, R, 2010)
"These findings suggest that the low-dose combination therapy of nifedipine CR and candesartan is superior to the up-titrated monotherapy of candesartan in terms of blood pressure control and renal protection in patients with essential hypertension."9.11Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study. ( Hasebe, N; Kikuchi, K, 2005)
"CHILI T2D was a non-interventional, open-label, non-controlled, multicentre study in clinical practice that evaluated 4110 patients with type 2 diabetes, uncontrolled hypertension and microalbuminuria who were being prescribed a fixed-dose combination of candesartan cilexetil 16 mg/HCTZ 12."5.14Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study. ( Bramlage, P; Ketelhut, R, 2010)
"These findings suggest that the low-dose combination therapy of nifedipine CR and candesartan is superior to the up-titrated monotherapy of candesartan in terms of blood pressure control and renal protection in patients with essential hypertension."5.11Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study. ( Hasebe, N; Kikuchi, K, 2005)
"Fifty-two patients with type 2 diabetes with normo- and microalbuminuria participated in this study."2.71Low-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure. ( Adachi, M; Hirano, T; Ikejiri, R; Murayama, S; Okada, K; Sakaue, T, 2003)
"Many patients with diabetic nephropathy (DN) have levels of albuminuria > 1 g/day and blood pressure >135/85 mmHg, despite antihypertensive combination therapy, including recommended doses of ACE inhibitors, e."2.70Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. ( Christensen, PK; Jensen, BR; Parving, HH; Rossing, K, 2002)
"Candesartan cilexetil is an angiotensin II type 1 (AT[1]) receptor antagonist (angiotensin receptor blocker [ARB]) that inhibits the actions of angiotensin II on the renin-angiotensin-aldosterone system."2.47Differential clinical profile of candesartan compared to other angiotensin receptor blockers. ( Cernes, R; Mashavi, M; Zimlichman, R, 2011)
" RI was compared to the ARB, candesartan (3 mg/kg/day PO), and to the ACEI, enalapril (60 mg/kg/day PO) in a 4-week dosing paradigm."1.35A nonpeptide, piperidine renin inhibitor provides renal and cardiac protection in double-transgenic mice expressing human renin and angiotensinogen genes. ( Carlson, T; Kowala, MC; Leadley, R; Major, TC; Okerberg, C; Olszewski, B; Ostroski, R; Rosebury, W; Schroeder, R, 2008)

Research

Studies (15)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (26.67)18.2507
2000's8 (53.33)29.6817
2010's3 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hayashi, K2
Sasamura, H1
Nakamura, M1
Sakamaki, Y1
Azegami, T1
Oguchi, H1
Tokuyama, H1
Wakino, S1
Itoh, H1
Major, TC1
Olszewski, B1
Rosebury, W1
Okerberg, C1
Carlson, T1
Ostroski, R1
Schroeder, R1
Kowala, MC1
Leadley, R1
Ketelhut, R1
Bramlage, P1
Cernes, R1
Mashavi, M1
Zimlichman, R1
Murayama, S1
Hirano, T1
Sakaue, T1
Okada, K1
Ikejiri, R1
Adachi, M1
Kakizawa, H1
Itoh, Y1
Imamura, S1
Matsumoto, T1
Ishiwata, Y1
Ono, Y1
Yamamoto, K1
Kato, T1
Hayakawa, N1
Oda, N1
Goto, Y2
Nagasaka, A1
Senda, T1
Itoh, M1
Rosei, EA1
Rizzoni, D1
Muiesan, ML1
Sleiman, I1
Salvetti, M1
Monteduro, C1
Porteri, E1
Hasebe, N1
Kikuchi, K1
Kim, S1
Ohta, K1
Hamaguchi, A1
Omura, T1
Yukimura, T1
Miura, K1
Inada, Y1
Wada, T1
Ishimura, Y2
Chatani, F1
Kohara, K1
Mikami, H1
Okuda, N1
Higaki, J1
Ogihara, T1
Obata, J1
Nakamura, T2
Kuroyanagi, R1
Yoshida, Y1
Guo, DF1
Inagami, T1
Casellas, D1
Benahmed, S1
Artuso, A1
Jover, B1
Ushiyama, C1
Suzuki, S1
Shimada, N1
Sekizuka, K1
Ebihara, I1
Takahashi, Y1
Tanaka, A1
Koide, H1
Rossing, K1
Christensen, PK1
Jensen, BR1
Parving, HH1
Matsuo, T1
Ishikawa, E1
Ohta, M1
Shibouta, Y1
Imura, Y1
Sugiyama, Y1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase I Non-Randomized, Unblinded, Single-Center Trial of Oral Telmisartan Alone or Combined With Selected Standard of Care Therapies for Prostate Cancer[NCT06168487]Early Phase 142 participants (Anticipated)Interventional2024-01-01Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for candesartan cilexetil and Albuminuria

ArticleYear
Differential clinical profile of candesartan compared to other angiotensin receptor blockers.
    Vascular health and risk management, 2011, Volume: 7

    Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Arteries; Benzimidazoles; Biphenyl Compounds;

2011

Trials

6 trials available for candesartan cilexetil and Albuminuria

ArticleYear
Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study.
    Clinical drug investigation, 2010, Volume: 30, Issue:5

    Topics: Aged; Albuminuria; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diab

2010
Low-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2003, Volume: 26, Issue:6

    Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphe

2003
Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus.
    Journal of hypertension, 2005, Volume: 23, Issue:2

    Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inh

2005
Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study.
    Journal of hypertension, 2005, Volume: 23, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Benzimidazoles; Bi

2005
Comparison between the angiotensin II receptor antagonist candesartan cilexetil and the angiotensin-converting enzyme inhibitor trandolapril in microalbuminuria of patients with early diabetic nephropathy.
    Nephron, 2000, Volume: 86, Issue:2

    Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte

2000
Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.
    Diabetes care, 2002, Volume: 25, Issue:1

    Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive

2002

Other Studies

8 other studies available for candesartan cilexetil and Albuminuria

ArticleYear
Renin-angiotensin blockade resets podocyte epigenome through Kruppel-like Factor 4 and attenuates proteinuria.
    Kidney international, 2015, Volume: 88, Issue:4

    Topics: Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphe

2015
A nonpeptide, piperidine renin inhibitor provides renal and cardiac protection in double-transgenic mice expressing human renin and angiotensinogen genes.
    Cardiovascular drugs and therapy, 2008, Volume: 22, Issue:6

    Topics: Administration, Oral; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin

2008
Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2004, Volume: 36, Issue:7

    Topics: Albuminuria; Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I

2004
Renal protective effect of TCV-116 in stroke-prone spontaneously hypertensive rats.
    Blood pressure. Supplement, 1994, Volume: 5

    Topics: Albuminuria; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Ben

1994
Angiotensin blockade and the progression of renal damage in the spontaneously hypertensive rat.
    Hypertension (Dallas, Tex. : 1979), 1993, Volume: 21, Issue:6 Pt 2

    Topics: Albuminuria; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzi

1993
Candesartan prevents the progression of glomerulosclerosis in genetic hypertensive rats.
    Kidney international. Supplement, 1997, Volume: 63

    Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds;

1997
Candesartan and progression of preglomerular lesions in N(G)-nitro-L-arginine methyl ester hypertensive rats.
    Journal of the American Society of Nephrology : JASN, 1999, Volume: 10 Suppl 11

    Topics: Albuminuria; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Bip

1999
Renal protective effect of candesartan cilexetil in spontaneously hypercholesterolemic rats.
    Japanese journal of pharmacology, 2002, Volume: 88, Issue:3

    Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Be

2002